Biological Basis for Understanding Psychopharmacology
Neuroimaging in Biological Psychiatry
Advanced Imaging Techniques
Positron-Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT):
Localize specific brain regions associated with perceptual, cognitive, emotional, and behavioral functions.
Provide objective evidence of altered metabolic activity and glucose utilization in unmedicated individuals diagnosed with major depressive disorder, schizophrenia, or obsessive-compulsive disorder (OCD).

Functional Magnetic Resonance Imaging (fMRI):
Measures functional connectivity and communication efficiency between distinct anatomical regions of the brain.
Demonstrates higher-order cognitive processing in real time.
Holds predictive clinical potential for identifying patient-specific treatment responses to psychotropic medications.
Biological Basis of Psychiatric Illness and Psychotropic Action
Pathophysiology and Biological Etiology
Anatomical Locus: All conscious and unconscious mental activity originates within functional neural networks in the brain.
Multifactorial Etiology: Psychiatric illnesses develop through complex interactions among diverse factors:
Genetic susceptibility
Neurodevelopmental abnormalities
Pharmacological exposures
Infectious agents
Psychosocial and environmental experiences
Biological Mechanism: Psychiatric conditions manifest as alterations in neurotransmitter synthesis, release, reuptake, or receptor sensitivity. These biological alterations serve as primary targets for psychotropic interventions.
Principles of Nursing Practice in Psychopharmacology
Core Goals of Psychiatric Mental Health Nursing:
Develop a comprehensive understanding of the neurobiological mechanisms underlying normal and abnormal brain functions.
Integrate neurobiological evidence into clinical assessment, monitoring, and administration of psychotropic drug regimens.
Neuroanatomy and Brain Functions
Fundamental Functions of the Brain
Maintenance of bodily homeostasis.
Regulation of the autonomic nervous system (ANS) and endocrine/hormonal pathways.
Control of basic biological drives (hunger, thirst, sex) and complex behaviors.
Regulation of the sleep-wake cycle and circadian rhythms.
Processing of conscious mental activity, executive functioning, and decision-making.
Storage and retrieval of memory.
Mediation of social behaviors and interpersonal interactions.
Brain Structures and Functional Localization

Frontal Lobe:
Primary seat of executive function and thought processes.
Responsible for goal formulation and selection, initiation, planning, and termination of actions.
Mediates decision-making, insight, motivation, and social judgment.
Location of origin for voluntary motor commands.
Parietal Lobe:
Somatosensory processing and motor integration.
Receives and interprets sensory inputs.
Controls concept formation, abstract thinking, proprioception, and body awareness.
Mediates reading comprehension, mathematical calculations, and right-left spatial orientation.
Temporal Lobe:
Auditory processing center.
Responsible for language comprehension and sound memory storage.
Direct connectivity with the limbic system ("the emotional brain"), allowing expression of primary emotions including fear, aggression, and sexual behavior.
Occipital Lobe:
Primary visual processing center.
Interprets visual imagery, visual association, and visual memory storage.
Integrates visual input into language formation pathways.
Cerebellum:
Coordinates skeletal muscle contractions and fine motor control.
Maintains postural balance and equilibrium.
Brainstem Structures:
Midbrain: Mediates pupillary reflexes and extraocular movements.
Pons: Functions as a major processing station within auditory pathways.
Medulla Oblongata: Contains autonomic reflex centers controlling balance, heart rate, respiratory depth and rate, coughing, swallowing, sneezing, blood pressure regulation, and vomiting.
Pituitary Gland (Anterior and Posterior): Master endocrine regulator controlling peripheral hormone release under hypothalamic control.
Cellular Mechanisms of Neurotransmission
Electrical and Chemical Signal Conduction
Neurotransmission Process:
Electrical impulse propagation (conduction) travels down the neuronal axon via rapid membrane depolarization and repolarization, mediated by influx of sodium () ions and efflux of potassium () ions.
Arrival of the action potential at the presynaptic terminal triggers vesicular release of chemical neurotransmitters across the synaptic cleft.
Neurotransmitters bind to specific postsynaptic receptors, inducing either excitatory or inhibitory responses in the postsynaptic cell.

Synaptic Transmission Abnormalities:
Insufficient Transmission: Caused by deficient presynaptic neurotransmitter synthesis/release or a reduction in postsynaptic receptor density.
Excessive Transmission: Caused by abnormally elevated presynaptic release or heightened postsynaptic receptor sensitivity (e.g., elevated dopamine signaling in schizophrenia).
Neurotransmitter Inactivation Pathways
Enzymatic Degradation: Immediate chemical inactivation of neurotransmitters by specific enzymes located within the synaptic cleft or postsynaptic membrane following receptor detachment.
Presynaptic Reuptake: Active transport mechanism where intact neurotransmitters separate from receptors and are transported back into the presynaptic neuron for repackaging into vesicles or intracellular degradation.
Receptor Pharmacodynamics
Receptors: Cell-surface or intracellular protein structures that bind specific chemical ligands to alter cellular physiology.
Receptor Agonist: An extrinsic drug molecule that binds to a receptor and mimics the action of endogenous ligands, producing a full physiological response.
Receptor Antagonist: An extrinsic drug molecule that binds to a receptor site without activating it, competitively or non-competitively blocking endogenous ligands from binding.
Major Neurotransmitter Systems
Monoamines
Dopamine (DA):
Decrease: Associated with depression and Parkinson's disease.
Increase: Associated with schizophrenia, psychosis, and mania.
Norepinephrine (NE):
Decrease: Associated with depression.
Increase: Associated with anxiety disorders, mania, and schizophrenia.
Serotonin ():
Decrease: Associated with major depressive disorder.
Increase: Associated with anxiety states and serotonin toxicity.
Histamine ():
Decrease: Results in sedation, drowsiness, and weight gain.
Amino Acids
Gamma-Aminobutyric Acid (GABA):
Main inhibitory neurotransmitter in the central nervous system.
Decrease: Associated with anxiety disorders, mania, and schizophrenia.
Increase: Reduces anxiety, induces sedation, and produces anticonvulsant effects.
Glutamate:
Main excitatory neurotransmitter in the central nervous system.
NMDA Receptor Hypofunction/Decrease: Impairs learning and memory.
NMDA Receptor Hyperfunction/Increase: Induces excitotoxicity and neurodegeneration (seen in Alzheimer's disease).
AMPA Receptor Activation: Enhances cognitive performance and memory formation.
Cholinergics
Acetylcholine (ACh):
Plays a crucial role in memory, learning, and motor control.
Decrease: Characteristic of Alzheimer's disease, Huntington's chorea, and Parkinson's disease.
Increase: Associated with depressive symptoms.
Neuropeptides / Neuromodulators
Substance P: Regulates mood, stress responses, anxiety, and pain transmission pathways.
Somatostatin (SRIF):
Decrease: Observed in Alzheimer's disease and in the cerebrospinal fluid (CSF) of depressed individuals.
Increase: Observed in Huntington's chorea.
Neurotensin: Decreased CSF concentrations noted in individuals with schizophrenia.
Pharmacokinetic and Pharmacodynamic Principles
Drug Interaction Categories
Pharmacokinetic Interactions:
Occur when one drug alters the absorption, distribution, metabolism (e.g., Cytochrome P450 inhibition/induction), or elimination of another agent.
Directly alters plasma drug concentrations.
Pharmacodynamic Interactions:
Occur when drugs exert actions on identical or interconnected receptor systems.
Result in additive, synergistic, or antagonist physiological effects.
Polypharmacy and Clinical Complexity
Managing drug interactions becomes complex in patients with multiple medical comorbidities.
Older adults face heightened risk due to age-related decline in hepatic clearance, renal filtration, and increased likelihood of polypharmacy.
Antidepressant Medications
Monoamine Oxidase Inhibitors (MAOIs)
Mechanism of Action: Inhibit the monoamine oxidase (MAO) enzyme responsible for catabolizing monoamine neurotransmitters (dopamine, norepinephrine, epinephrine, serotonin), thereby increasing synaptic monoamine availability.
Drug Classifications:
Oral Agents: Phenelzine (Nardil), Tranylcypromine (Parnate), Isocarboxazid (Marplan).
Transdermal System: Selegiline transdermal system (EMSAM) — delivers MAOIs continuously through the skin.

Hypertensive Crisis:
Occurs when patients taking MAOIs ingest tyramine-containing substances or sympathomimetic drugs.
Tyramine acts as an indirect sympathomimetic agent, triggering massive norepinephrine release.
Restricted Foods: Aged cheeses, milk products, Chianti wine, draft beer, preserved/cured meats (salami), avocados, organ meats, overripe fruit.
Contraindicated Medications ("No Popular Meds Ever"): Tricyclic antidepressants, SSRIs, indirect-acting sympathomimetics, antihypertensives, OTC cold/cough remedies, asthma inhalers, decongestants.
Dietary Restrictions Timeline: Tyramine restrictions must be strictly maintained during therapy and for at least following drug discontinuation.
Clinical Presentation: Severe occipital headache, profuse sweating, palpitations, nausea, vomiting, severe hypertension, tachycardia.
Emergency Nursing Interventions:
Immediately discontinue the MAOI.
Assess and monitor vital signs.
Administer short-acting antihypertensive agents (e.g., phentolamine or nitroprusside).
Apply cooling blankets or tepid baths for hyperthermia.
Manage symptoms and maintain airway.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Representative Agents: Fluoxetine (Prozac), Sertraline (Zoloft), Paroxetine (Paxil), Citalopram (Celexa), Escitalopram (Lexapro).
Mechanism of Action: Selectively block the presynaptic reuptake transporter for serotonin (), increasing synaptic concentration.
Clinical Indications: Major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder.
Onset of Action: Therapeutic response requires of continuous administration.

Common Side Effects:
Gastrointestinal upset (nausea, vomiting, diarrhea)
Headache, insomnia, or somnolence
Lethargy and fatigue
Sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction)
Weight gain
Significantly fewer anticholinergic effects compared to tricyclic antidepressants.
Herbal Interactions: St. John's Wort must be avoided due to severe risk of serotonin toxicity.
Antidepressant Discontinuation Syndrome:
Occurs following abrupt cessation of SSRI therapy.
Clinical Mnemonic (FINISH):
F: Flu-like symptoms (lethargy, myalgias)
I: Insomnia with vivid dreams or nightmares
N: Nausea (occasionally vomiting)
I: Imbalance (dizziness, vertigo, lightheadedness)
S: Sensory disturbances (paresthesias, "brain zaps")
H: Headaches
FDA Black Box Warning: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (). Requires close clinical monitoring for worsening depression or emergence of suicidality.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Representative Agents: Venlafaxine (Effexor), Duloxetine (Cymbalta).
Mechanism of Action: Dual inhibition of presynaptic serotonin and norepinephrine reuptake transporters.
Side Effect Profile: Similar to SSRIs with low anticholinergic activity; can cause dose-dependent elevations in blood pressure.
Serotonin Syndrome
Etiology: Potentially fatal hyper-serotonergic state caused by excessive serotonergic stimulation. High risk occurs when combining SSRIs with MAOIs, lithium, meperidine, triptans, or cocaine, or following rapid dose titration.
Onset: Rapid onset, typically within of drug administration or dosage change.

Clinical Mnemonic (SHIVERS):
S: Shivering
H: Hyperreflexia and myoclonus
I: Increased temperature (hyperthermia)
V: Vital sign instability (autonomic instability, tachycardia, labile BP)
E: Encephalopathy (mental status changes: confusion, agitation, lethargy, coma)
R: Restlessness and motor hyperactivity
S: Sweating (diaphoresis)
Differential Diagnosis: Unlike Anticholinergic Toxidrome (which presents with dry skin and absent bowel sounds), Serotonin Syndrome features diaphoresis, hyperactive bowel sounds, nausea, vomiting, and diarrhea ("hot and wet").
Nursing and Emergency Interventions:
Discontinue all serotonergic agents immediately.
Notify healthcare provider.
Expect order for Cyproheptadine (a and receptor antagonist).
Implement cooling blankets or tepid sponge baths.
Provide continuous vital sign monitoring, fluid management (I&O), and seizure precautions.
Tricyclic Antidepressants (TCAs)
Representative Agents: Amitriptyline (Elavil), Nortriptyline (Pamelor), Doxepin (Sinequan), Imipramine (Tofranil).
Mechanism of Action: Non-selectively inhibit reuptake of norepinephrine and serotonin. Also block muscarinic acetylcholine, histamine , and alpha-1 adrenergic receptors.
Clinical Indications: Endogenous depression, reactive depression, and depression associated with alcohol or cocaine withdrawal.
Onset: Requires for therapeutic efficacy. Do not stop abruptly.

Side Effect Profile:
Sedation (histamine blockade)
Orthostatic hypotension and reflex tachycardia (alpha-1 blockade)
Decreased sexual desire/ability
Weight gain
Anticholinergic Side Effects and Toxidrome:
"Blind as a bat": Mydriasis (dilated pupils), loss of accommodation, blurred vision.
"Hot as a desert": Hyperthermia due to suppression of sweating.
"Red as a beet": Flushed, vasodilation of cutaneous blood vessels.
"Dry as a bone": Dry mouth (xerostomia), urinary retention, constipation, absent bowel sounds.
"Mad as a hatter": Confusion, delirium, hallucinations, agitation, fine tremors, picking at invisible objects.
Cardiac Toxicity: Risk of lethal cardiac dysrhythmias (QRS prolongation) in overdose.

Other Antidepressant Classes
Serotonin-Norepinephrine Disinhibitors (SNDIs):
Enhance serotonin and norepinephrine release.
Used in combination with SSRIs to augment efficacy or counter serotonergic side effects (e.g., sexual dysfunction).
Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs):
Example: Bupropion (Wellbutrin).
Mechanism: Inhibits dopamine and norepinephrine reuptake with no action on serotonin. Inhibits nicotinic acetylcholine receptors to aid smoking cessation.
Caution: Dose-dependent risk of seizures; contraindicated in eating disorders.
Serotonin Antagonist/Reuptake Inhibitors (SARIs):
Example: Trazodone (Desyrel).
Clinical Use: Second-line antidepressant, highly sedating, commonly prescribed off-label for insomnia.
Adverse Effect: Risk of priapism (painful, sustained erection requiring medical intervention).
Selective Norepinephrine Reuptake Inhibitors (NRIs):
Example: Atomoxetine (Strattera).
Indication: Treatment of ADHD in patients who cannot tolerate stimulants; lacks significant antidepressant efficacy.
Antianxiety and Sedative-Hypnotic Medications
Anxiolytic Classes and Mechanisms
Therapeutic Uses: Treatment of acute and chronic anxiety disorders, acute alcohol withdrawal symptoms, skeletal muscle spasms, convulsive disorders, and preoperative sedation.
Mechanism of Action: Depress subcortical CNS levels by potentiating GABA activity (increasing chloride ion channel influx), causing neuronal hyperpolarization resulting in sedation, hypnosis, or coma.

Benzodiazepines:
Anxiolytic Focus: Diazepam (Valium), Clonazepam (Klonopin), Alprazolam (Xanax), Lorazepam (Ativan).
Note: Lorazepam and Alprazolam provide therapeutic anxiolysis with less soporific (sleep-inducing) sedation at lower doses.
Insomnia Focus: Flurazepam (Dalmane), Triazolam (Halcion).
Non-Benzodiazepine Anxiolytics:
Buspirone (Buspar): Reduces anxiety without producing sedation, muscle relaxation, cognitive impairment, or euphoric effects. Low abuse potential; does not cause physical dependence.
Short-Acting Sedative-Hypnotics and Melatonin Agonists
Non-Benzodiazepine "Z-Hypnotics":
Agents: Zolpidem (Ambien), Zaleplon (Sonata), Eszopiclone (Lunesta).
Action: Selective binding to GABA receptor subunits to induce sedative/hypnotic effects without antianxiety, anticonvulsant, or muscle relaxant properties.
Melatonin-Receptor Agonist:
Ramelteon (Rozerem): Hypnotic agent that acts selectively on melatonin and receptors in the suprachiasmatic nucleus to regulate circadian sleep cycles.
Patient Safety and Nursing Considerations
High potential for physical and psychological dependence with long-term benzodiazepine use.
Common Side Effects: Central nervous system depression—drowsiness, confusion, ataxia, lethargy, orthostatic hypotension.
Severe Interactions: Concomitant use with alcohol, opioid analgesics, other CNS depressants, sedating antihistamines, cimetidine, TCAs, neuromuscular blockers, or disulfiram can lead to severe respiratory depression, coma, and death.
Mood Stabilizers
Lithium Carbonate
Representative Formulations: Lithobid, Lithonate, Lithotabs.
Mechanism of Action: Alters sodium ion transport in nerve and muscle cells; inhibits presynaptic release of norepinephrine and dopamine; alters intracellular second messenger systems (e.g., inositol phospholipid pathway).
Therapeutic Index: Narrow therapeutic window requiring routine serum blood concentration monitoring.
Blood Level Ranges:
Acute Mania Level:
Maintenance Level:
Toxic Level:
Long-Term Adverse Effects: Chronic lithium usage increases the risk of renal failure (nephrogenic diabetes insipidus) and thyroid disorders (hypothyroidism).
Common Side Effects: Drowsiness, dizziness, headache, dry mouth, polydipsia (thirst), GI distress (nausea/vomiting), fine hand tremor, hypotension, pulse dysrhythmias, polyuria, dehydration, weight gain.
Signs of Lithium Toxicity:
Initial/Early Toxicity: Blurred vision, ataxia, tinnitus, persistent nausea/vomiting, severe watery diarrhea.
Advanced Toxicity: Severe or coarse hand tremors, severe GI pain, unsteadiness/stumbling gait, slurred speech (dysarthria), muscle twitching/fasciculations, clumsiness, severe confusion, muscle weakness, seizures, coma.
Nursing Considerations: Ensure adequate dietary fluid () and consistent sodium intake. Hyponatremia inhibits lithium excretion, leading to toxic accumulation.
Anticonvulsant Mood Stabilizers
Valproate / Valproic Acid (Depakote, Depakene):
First-line for bipolar patients unresponsive to lithium or experiencing rapid-cycling.
Inhibits metabolism of lamotrigine, increasing its serum concentrations.
Side Effects: Nausea, vomiting, drowsiness, dizziness, blood dyscrasias, prolonged bleeding time, hepatotoxicity, pancreatitis.
Lamotrigine (Lamictal):
Effective for bipolar depression maintenance.
Dermatological Warning: High risk for triggering a life-threatening, severe cutaneous reaction known as Stevens-Johnson Syndrome (SJS).
Patient Teaching: Instruct patient to report any skin rash immediately.

Carbamazepine (Tegretol):
Effective in rapid-cycling bipolar disorder and acute mania.
Adverse Effects: Rare but fatal blood dyscrasias (agranulocytosis, aplastic anemia).
Topiramate (Topamax): Off-label mood stabilizer; reduces efficacy of oral contraceptives; weight neutral or weight loss.
FDA Black Box Warning (December 2008): All antiepileptic/anticonvulsant drugs carry an increased risk of suicidal thoughts and behaviors.
Off-Label Mood Stabilizers: Oxcarbazepine (Trileptal), Gabapentin (Neurontin), Topiramate (Topamax).
Patient and Family Education:
Do not stop taking anticonvulsants abruptly.
Immediately report: skin rash, unusual bleeding, spontaneous bruising, sore throat, fever, malaise, dark urine, or yellowing of skin/eyes (jaundice).
Avoid alcohol and OTC drugs without physician approval.
Antipsychotic Medications
Overview and Clinical Goals
Indication: Alleviate psychotic symptoms (delusions, hallucinations, thought disorganization) associated with schizophrenia and bipolar disorder.
Cure vs. Symptom Management: Antipsychotics control symptoms but do not cure the underlying psychiatric condition. Medication non-adherence leads to rapid symptom relapse.
Categorization:
First-Generation Antipsychotics (FGA / Conventional / Typical).
Second-Generation Antipsychotics (SGA / Atypical).
Clinical Features of Schizophrenia

Positive Symptoms (Excess or distortion of normal function - should not be present):
Visual hallucinations
Auditory hallucinations
Delusional thinking
Disorganized speech and behavior
Agitated, catatonic, or repetitive motor movements
Negative Symptoms (Deficit or loss of normal function - should be present):
Flat or blunted affect
Social isolation and withdrawal
Apathy
Anergia (lack of energy)
Anhedonia (inability to feel pleasure)
Alogia (reduced speech content)
First-Generation Antipsychotics (FGAs)
Mechanism of Action: Dopamine receptor antagonists (DRAs) that selectively block Dopamine type 2 () receptors in the brain, reducing dopaminergic transmission.
Therapeutic Spectrum: Target positive symptoms of schizophrenia effectively; ineffective for negative symptoms.
Subclasses by Potency:
High-Potency: Haloperidol (Haldol), Fluphenazine (Prolixin) — high risk of EPS, lower anticholinergic/sedative effects.
Moderate-Potency: Perphenazine (Trilafon).
Low-Potency: Chlorpromazine (Thorazine) — low risk of EPS, high sedating, hypotensive, and anticholinergic effects.
Extrapyramidal Side Effects (EPS) and Adverse Reactions

Acute Dystonia:
Sudden, painful muscle spasms/stiffness of the face, neck, back, or tongue (back spasms cause trunk to arch forward).
Facial grimacing, involuntary upward eye movement (oculogyric crisis).
Laryngeal spasms (medical emergency threatening airway).
Akathisia:
Subjective intense motor restlessness.
Inability to sit still, pacing the floor, constant shifting of feet, rocking back and forth.
Pseudoparkinsonism:
Drug-induced parkinsonian symptoms.
Stooped posture, shuffling gait, muscle rigidity, bradykinesia, resting tremors, pill-rolling motion of the hand.
Tardive Dyskinesia (TD):
Involuntary, irreversible neurological movement disorder resulting from chronic blockade.
Protrusion and rolling of the tongue, sucking and lip-smacking, chewing movements, facial dyskinesia, choreoathetoid movements of the trunk and extremities.
Neuroleptic Malignant Syndrome (NMS):
Rare, life-threatening emergency occurring after starting or escalating FGA therapy (or abrupt withdrawal of dopaminergic agonists in Parkinson's).

Clinical Mnemonic (FEVER):
F: Fever (hyperthermia, temperature /)
E: Encephalopathy / Altered Mental Status (AMS)
V: Vitals instable (autonomic instability: tachycardia, labile BP, tachypnea)
E: Elevated CPK (creatine phosphokinase due to severe rhabdomyolysis) and Leukocytosis
R: Rigidity ("lead-pipe" muscle rigidity)
Classic NMS Tetrad: Altered mental status, extreme hyperthermia, severe muscle rigidity, autonomic instability.
Receptor Blockade Side Effect Profiles

Dopamine Receptor Blockade:
Antipsychotic effect (reduces positive symptoms).
Extrapyramidal side effects (EPS).
Hyperprolactinemia: Men (gynecomastia), Women (galactorrhea, amenorrhea).
Muscarinic Cholinergic Receptor Blockade:
Dry mouth, blurred vision, urinary retention/hesitancy, constipation, tachycardia.
Histamine Receptor Blockade:
Sedation, drowsiness, substantial weight gain, orthostasis.
Alpha-1 () Adrenergic Blockade:
Peripheral vasodilation, orthostatic hypotension, dizziness, reflex tachycardia, ejaculatory failure.
Alpha-2 () Adrenergic Blockade:
Sexual dysfunction, priapism.
Serotonin Receptor Blockade:
Antipsychotic effect, weight gain, hypotension, ejaculatory dysfunction.
GABA Modulation:
Lowers seizure threshold.
Second-Generation (Atypical) Antipsychotics (SGAs)
Mechanism of Action: Dual serotonin-dopamine antagonists (block and receptors).
Therapeutic Advantages:
Effectively target both positive and negative symptoms of schizophrenia.
Significantly lower risk of extrapyramidal side effects (EPS) and tardive dyskinesia.
Help treat comorbid anxiety and depressive symptoms; reduce suicidal behaviors.
Improve overall functional quality of life.
Representative SGA Agents:
Clozapine (Clozaril) — requires regular blood monitoring for agranulocytosis risk.
Olanzapine (Zyprexa)
Risperidone (Risperdal)
Quetiapine (Seroquel)
Ziprasidone (Geodon)
Aripiprazole (Abilify) — dopamine system stabilizer / partial agonist.
Iloperidone (Fanapt)
Lurasidone HCl (Latuda)
Cariprazine (Vraylar)
Major Metabolic Risk (Metabolic Syndrome):
Substantial weight gain
Hyperglycemia / New-onset type 2 diabetes mellitus
Dyslipidemia (increased serum triglycerides)
Insulin resistance
Diagnostic Comparison of Key Syndromes
Differential Diagnosis Matrix
Serotonin Syndrome:
Primary Cause: Serotonergic agents (SSRIs, SNRIs, MAOIs, Triptans).
Onset: Rapid ().
Neuromuscular Findings: Hyperreflexia, myoclonus, shivering, tremor.
Autonomic/Skin Signs: Diaphoresis ("wet"), hyperactive bowel sounds, diarrhea, nausea.
Treatment: Discontinue drug, Cyproheptadine, cooling measures.
Neuroleptic Malignant Syndrome (NMS):
Primary Cause: Antipsychotic agents ( blockers) or dopaminergic withdrawal.
Onset: Gradual ().
Neuromuscular Findings: Severe "lead-pipe" rigidity, bradykinesia, tremors.
Autonomic/Skin Signs: Diaphoresis, extreme fever, labile blood pressure, elevated CPK, leukocytosis.
Treatment: Discontinue drug, Dantrolene or Bromocriptine, intensive cooling.
Anticholinergic Toxicity:
Primary Cause: TCAs, Low-potency FGAs, Antihistamines, Antiparkinsonian drugs.
Neuromuscular Findings: Delirium, ataxia, shaking, grabbing invisible objects.
Autonomic/Skin Signs: Flushed skin ("red"), hyperthermia, dry skin/mouth ("dry as a bone"), urinary retention, absent bowel sounds.
Treatment: Discontinue drug, Physostigmine (if indicated), supportive care.